We examined serum cytokeratin 18 fragment (CK18F) as a noninvasive marker for predicting treatment response and “at-risk MASH” and “MASH resolution” in patients with MASLD. Here, KRT18 is linked to metabolic dysfunction-associated steatohepatitis.